Insiders' dealing Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and persons/companies closely associated with these Pursuant to section 28a of the Danish Act on Securities Trading, NeuroSearch A/S (NEUR.CO) shall make public, transactions with shares and related securities of NeuroSearch A/S by persons discharging managerial responsibilities and persons/companies closely associated with these. Name: Jette Møllmann Reason: Vice President, Director of Legal Affairs Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date: 12 March 2008 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 1,545 Market value (DKK): 435,690 Name: Daniel Brunicardi Timmermann Reason: Vice President, Director of Ion Channel Therapeutics Issuer and ID code / ISIN: NeuroSearch A/S / DK0010224666 Transaction: Sale of shares Trading date: 12 March 2008 Market: The OMX Nordic Exchange Copenhagen A/S Number (pcs): 1,545 Market value (DKK): 435,690 Contact person: Anita Milland, Vice President, CFO, telephone: +45 2016 3432 NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 12 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases - both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.
Report of transactions with shares and related securities of NeuroSearch by persons discharging managerial responsibilities and persons/companies closely associated with these
| Source: NTG Nordic Transport Group A/S